Drug Profile
Research programme: anti-inflammatory nanobody-based therapeutics - Ablynx/Sanofi
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Ablynx; Sanofi
- Class Anti-inflammatories; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Inflammation in Belgium (Parenteral)
- 28 Aug 2021 No recent reports of development identified for research development in Inflammation in France (Parenteral)
- 11 Feb 2021 i2O Therapeutics signs agreement with Sanofi for development of Nanobody based oral medicine